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Background: Several in vitro studies have shown that at similar tidal volume (VT),
bronchodilator delivery to target sites is signiﬁcantly lower during controlled
mechanical ventilation (CMV) than that during simulated spontaneous breathing.
However, the inﬂuence of active respiratory efforts on the magnitude of b2-agonist
induced bronchodilation in mechanically ventilated patients has not been examined.
Objective: To examine the inﬂuence of controlled and assisted modes of ventilatory
support on the bronchodilative effect induced by b2-agonists administered with a
metered dose inhaler (MDI) and a spacer device in a homogeneous group of
mechanically ventilated patients with acute exacerbation of chronic obstructive
pulmonary disease (COPD).
Methods: Prospective clinical study. Ten mechanically ventilated patients with
acute exacerbation of COPD were prospectively randomized to receive 4 puffs of
salbutamol (S, 100 mg/puff) either with volume-controlled (VC) or pressure-support
(PS) ventilation. On PS the pressure level was such that VTwas comparable between
ventilatory modes. After a 6-h washout period, patients were crossed-over to
receive the drug by the alternative mode of ventilation. Static and dynamic airway
pressures, minimum (Rint) and maximum (Rrs) inspiratory resistance, the difference
between Rrs and Rint (DR), end-inspiratory static compliance of the respiratory
system (Crs), intrinsic positive end-expiratory pressure (PEEPi) and heart rate (HR)
were measured before and at 15, 30, 60, 120, 180 and 240min after S
administration.
Results: S caused a signiﬁcant decrease in dynamic and static airway pressures,
PEEPi, Rint and Rrs. These changes were not inﬂuenced by the ventilatory mode and
were evident at 15, 30, 60 and 120min after S. HR, Crs and DR did not change after S
administration.Elsevier Ltd. All rights reserved.
2 201510; fax: +30 2810 392636.
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Inﬂuence of respiratory efforts on b2-agonist 301Conclusions: Considering the use of propofol with its presumed bronchodilative
properties as a shortcoming of our study, it is concluded that the magnitude of
bronchodilation induced by salbutamol delivered by an MDI and a spacer device in
mechanically ventilated COPD patients is not affected by the presence or absence of
active respiratory efforts.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Studies have shown that in patients with acute
exacerbation of chronic obstructive pulmonary
disease (COPD), mechanically ventilated on con-
trolled modes (volume- or pressure-controlled),
manipulation of ventilator settings did not affect
bronchodilation induced by b2-agonists adminis-
tered with a metered-dose inhaler (MDI) and a
spacer device.1–4 Neither application of an end-
inspiratory pause time1 nor changes in tidal volume
(VT),2 inspiratory ﬂow pattern (square wave or
decelerating)3 and ﬂow rate4 inﬂuenced the effec-
tiveness of salbutamol administered using an MDI
and a large volume spacer device. Independent of
ventilator settings salbutamol administration re-
sulted in signiﬁcant bronchodilation, as indicated
by a considerable drop in inspiratory resistance and
intrinsic positive end-expiratory pressure (PEEP).
Although patients with acute exacerbation of
COPD needing invasive mechanical ventilation are
initially ventilated on controlled modes, it is
generally recommended that these patients should
be switched to assisted modes of ventilatory
support in order to initiate the weaning process as
soon as possible5,6 and avoid the well-known
complications associated with prolonged invasive
mechanical ventilation as well as to attenuate the
recently described phenomenon of ventilator-in-
duced diaphragmatic dysfunction.7 Thus, it is of
great interest to examine if the presence of
respiratory muscle activity would inﬂuence the
effectiveness of b2-agonists given by MDI and a
spacer device. In vitro studies have shown that at
similar VT, bronchodilator delivery to target sites is
signiﬁcantly lower during controlled mechanical
ventilation (CMV) than that during simulated
spontaneous breathing.8 Fok et al.9 have shown
that MDI delivery of aerosolized salbutamol to
ventilated normal rabbits resulted in higher pul-
monary deposition of the drug in nonparalyzed
animals with active respiratory efforts than that in
paralyzed animals. This difference in drug delivery,
however, may not necessarily result in a different
bronchodilative effect, as studies during CMV
indicate.10 Therefore, the aim of our study was to
examine the inﬂuence of controlled and assistedmodes of ventilatory support on the bronchodila-
tive effect induced by b2-agonists administered
with an MDI and a spacer in a homogeneous group of
patients with acute exacerbation of COPD. Pre-
liminary results of this study have been presented
in an abstract form.11Methods
Ten patients (aged 67.478.1 years [mean7SD];
nine males, one female) with COPD, requiring
endotracheal intubation and mechanical ventila-
tion to manage acute respiratory failure due to an
acute exacerbation of chronic airﬂow obstruction,
were studied. Patients with a diagnosis of bronchial
asthma, as well as patients with pneumonia,
pulmonary edema, refractory hypoxemia, pneu-
mothorax or excessive airway secretions were
excluded. All patients had a previous diagnosis of
COPD and met established criteria for this diag-
nosis.12 The study was approved by the Hospital
Ethics Committee and informed consent was
obtained from the patients or their families.
All patients were orotracheally intubated (low-
pressure cuff endotracheal tube, diameter
8.070.5mm, tube length 2871mm) sedated (pro-
pofol and remifentanyl) and initially ventilated (for
24–36 h) on volume-controlled (VC) mode (Evita 2,
Draeger, Luebeck, Germany), using settings that
minimized dynamic hyperinﬂation VT 7–8ml/kg,
square wave ﬂow-time proﬁle, no end-inspiratory
pause, zero PEEP) and a fractional concentration of
inspired O2 that achieved a hemoglobin saturation
489%. After this period, the patients were
switched to ﬂow-triggering pressure-support (PS)
ventilation with the level of pressure assist ad-
justed to obtain a VT comparable to that with VC.
During PS, extrinsic PEEP of approximately 1–2 cm
H2O lower than PEEPi, measured on controlled
mode, was applied. The threshold for triggering
was set to 2 l/min. Patients’ characteristics and
baseline ventilator settings are shown in Table 1.
Propofol and remifentayl infusions during VC and PS
mode were titrated such as to obtain sedation
levels 6 and 3 on the Ramsay scale, respectively.13
If patients were stable on PS with adequate gas
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67.4 0.40 0.49 14.4 0.69 0.23 7.18 0.48 16.1 14.5 5.9
78.1 70.07 70.02 71.74 70.02 70.03 70.95 70.03 72.02 74.3 71.1
Values are means7SD. FiO2: fractional concentration of inspired O2; VT (VC), VT (PS): tidal volume with volume control and
pressure support, respectively; Fr (VC), Fr (PS): breathing frequency with volume control and pressure support, respectively; VI:
constant inspiratory ﬂow; TI/TTOT: duty cycle; VE: minute ventilation; IPAP: assisting pressure (above PEEPe); PEEPe: external
positive end-expiratory pressure.
P. Malliotakis et al.302exchange, respiratory frequency less than 30
breaths/min and without clinical evidence of
excessive work of breathing, all bronchodilators
were withheld for 6 h. By the end of this period
patients were re-evaluated and if they had a
respiratory frequency of less than 30 breaths/min,
expiratory VT variation less than 15%, adequate gas
exchange and no clinical evidence of excessive
work of breathing they were prospectively rando-
mized to receive 4 puffs of salbutamol (S, 100 mg/
puff given by an MDI canister, Aerolin inhaler, Glaxo
Wellcome) being ventilated either on PS or VC
mode. On VC mode, VT and ventilator frequency
were set to values similar to these on PS. A square
wave ﬂow pattern was used and no end-inspiratory
pause time was applied. No manipulation was
performed on PS. After a 6 h washout-period, the
patients were crossed-over to receive the drug by
the alternative mode of ventilation. The MDI was
adapted to the inspiratory limb of the ventilator
circuit using an aerosol cloud enhancer spacer
(ACE, Diemolding Healthcare Division, USA), where-
by the MDI ﬂume is directed away from the patient.
The spacer was placed just before the Y-ventilator
connector. The canister was shaken before each
series of puffs. Each actuation was performed at
20–30 s intervals, immediately before initiation of
airﬂow by the ventilator on VC or before the sudden
drop in airway pressure on PS, which signaled the
start of the triggering process. Arterial blood gases
were measured before and 4 h after drug adminis-
tration. SaO2 was measured continuously using a
pulse oxymeter (Critikon, Tampa, FLA, USA). All
patients were ventilated in a semirecumbent
position, which was kept constant throughout the
study period and certain nursing interventions (e.g.
chest physiotherapy, suctioning) were withheld or
minimized, while the remaining aspects of patient
care (e.g. ﬂuids, nutrition) were at the discretion
of the treating physician.
The absence of respiratory muscle activity during
VC ventilation was based on speciﬁc criteria,
including absence of negative deﬂection of airwaypressure (Paw), stabilization of the Paw waveform,
constancy of peak inspiratory pressure from breath
to breath and exponential decline of expiratory
ﬂow.14
Flow at the airway opening was measured with a
heated pneumotachograph (Hans-Rudolf 3700, Kan-
sas, USA) and a differential pressure transducer
(Micro-Switch 140PC, Honeywell Ltd., Ontario,
Canada), placed between the endotracheal tube
and the ventilator. Flow was electronically inte-
grated to provide volume. Airway pressures (Paw;
Micro-Switch 140PC, Honeywell Ltd., Ontario,
Canada) were measured from a side port between
the pneumotachograph and the endotracheal tube.
All signals were sampled at 50Hz (Windaq Instru-
ments Inc., OH, USA) and stored on a computer disk
for later analysis.
Respiratory system mechanics and heart rate
(HR) were assessed before (baseline) and at 15, 30,
60, 120, 180 and 240min after each series of puffs.
The mechanical properties of the respiratory
system were determined while the patients were
ventilated on VC mode before switching to PS at
ventilator settings shown in Table 1. If the patients
received S while they were ventilated on PS,
respiratory system mechanics were measured by
switching them to volume controlled mode (at
ventilator settings shown in Table 1) after a bolus
administration of propofol at a dose of 1.0–2.0mg/
kg i.v. This dose effectively suppressed spontaneous
respiratory efforts for a brief period of approxi-
mately 3–5min. Respiratory system mechanics
were measured using the occlusion technique.15,16
In brief, the airways were occluded at end-
inspiration for 5 s and there was an immediate
drop in airway pressure from a peak (Ppk) to a lower
value (P1), followed by a gradual decay to a plateau
(P2). In each patient at least 3 breaths with a
satisfactory plateau were analyzed and the mean
values were reported. Intrinsic PEEP (PEEPi) was
measured by occluding the airways at the end
of a tidal expiration for 5 s and observing the
airway pressure. Again, 3 breaths were analyzed.
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system (Crs) as well as minimum (Rint) and max-
imum (Rrs) resistance of the respiratory system
were computed according to standard formu-
las.15,16 The difference between Rrs and Rint (DR),
caused by time-constant inequalities and/or vis-
coelastic behavior (stress relaxation), was also
calculated. Rint and Rrs were corrected for the
ﬁnite occlusion time of the occlusion valve of the
ventilator.17 The endotracheal tube resistance was
not taken into account, because each patient
served as his/her own control.
Data were analyzed by paired t-test and multi-
factorial analysis of variance for repeated mea-
surements (ANOVA). When the F value was
signiﬁcant, Tukey’s test was used to identify
signiﬁcant differences. A value of Po0:05 was
considered statistically signiﬁcant. Data are ex-
pressed as means7SD.Results
Baseline respiratory system mechanics before the
administration of each series of puffs of salbutamol
are shown in Table 2. There was no signiﬁcant
difference in any of these variables between the
two conditions of drug delivery (ANOVA). Further-
more, baseline arterial blood gases did not differ
signiﬁcantly between the two modes of salbutamol
administration (paired t-test). When salbutamol
was administered in VC mode, baseline pH, arterialTable 2 Airway pressures, respiratory system mechan
salbutamol administration in VC and PS.
VC
BL 15min 30min 60min 120min
Ppk 3774.8 34.175.6* 33.375.8* 33.476.5* 33.975.7*
P1 24.475.7 23.27* 22.776.1* 23.176.6* 23.376.1*
P2 18.975 17.975.1* 17.575* 17.575.4* 17.674.4*
Rint 18.474 15.973.5* 15.573.6* 15.173.8* 15.574*
Rrs 26.574.1 23.773.7* 23.173.6* 23.374.3* 23.974.4*
DR 8.172.2 7.872.2 7.672.3 8.272.3 8.473
Crs 50.4715.8 48.7712 48.7710 49.7715.1 50.2716.1
PEEPi 8.473.2 7.273.5* 7.173.5* 7.173.5* 7.473.6*
HR 83.2722.2 85.2722.2 81.5720 83.2719 80.7719.1
For reasons of clarity, data for 180 and 240min after salbutam
baseline; Ppk: peak airway pressure (cm H2O); P1: airway pressure
H2O); Rint, Rrs: minimum and maximum inspiratory resistance (cm
(cm H2O/l/s); Crs: end-inspiratory static compliance of the respira
heart rate (beats/min).
#Respiratory system mechanics were measured while the patient
time proﬁle.
*Signiﬁcantly different from baseline values (Po0.05, two-way Aoxygen tension (PaO2) and arterial carbon dioxide
tension (PaCO2) were 7.3770.04, 76.678 and
60.975.2mmHg, respectively, while the corre-
sponding values in PS mode were 7.3870.04,
74.377.3 and 61.978.2mmHg. Similarly, baseline
(before salbutamol administration) respiratory sys-
tem mechanics and arterial blood gases did not
differ during the six hours of observation (paired
t-test, P40:05). Speciﬁcally, the initial baseline
values of Rint and Rrs were 1874 and 26.374.4 cm
H2O/l/s respectively, whereas the corresponding
values after 6 h were 18.373.8 and 26.773.8 cm
H2O/l/s, indicating that factors other than salbu-
tamol did not appreciably affect lung function.
Baseline HR differed between the two ventilatory
modes (83.272.2 in VC mode versus 99.2710.7 in
PS mode) due to different levels of sedation.
Propofol was administered as a continuous i.v.
infusion at a dose of 310742 and 160730mg/h in VC
and PS mode, respectively. The corresponding values
for remifentanyl were 465745 and 155742mg/h,
respectively. In PS mode, patients received prior to
respiratory system mechanics measurement a bolus
of i.v. propofol at a dose ranging between 90 and
140mg (mean 117714mg).
The effects of salbutamol, administered during
VC and PS ventilation, on respiratory system
mechanics and HR are shown in Table 2. In both
ventilatory modes, 4 puffs of salbutamol caused a
signiﬁcant decrease in dynamic and static airway
pressures, Rint, Rrs and PEEPi (ANOVA). These
effects were evident at 15min after drug delivery
and maintained relatively constant for at least 2 h.ics] and heart rate before and up to 120min after
PS
BL 15min 30min 60min 120min
35.874. 32.274.6* 31.774.7* 32.375* 32.374.4*
23.474.8 21.875* 21.574.9* 22.275.1* 21.674.8*
18.174.6 16.574.5* 16.474.7* 16.974.7* 16.574.8*
18.174.3 15.373.5* 14.973.7* 14.874* 15.674.1*
25.874.8 2374* 22.474* 22.674* 23.173.6*
7.672.2 7.872.2 7.572.1 7.871.8 7.572.3
52714.1 52.5712.6 54.3713.2 51.3713.1 54.9713.9
872.7 6.872.9* 6.973.2* 6.873.1* 773*
99.2710.8 97.178 9777.2 97.278.2 99.479.3
ol administration are not shown.Values are means7SD. BL:
at the point of zero ﬂow (cm H2O); P2: plateau pressure (cm
H2O/l/s), respectively; DR: difference between Rrs and Rint
tory system (ml/cm H2O); PEEPi: intrinsic PEEP (cm H2O); HR:









































Figure 2 (A) Individual patient values of Rmin before and
P. Malliotakis et al.304Individual values of Rint, which reﬂects ‘‘ohmic’’
airway resistance, at baseline and 60min after
salbutamol administration are shown in Fig. 1. The
mode of ventilatory support did not have any
signiﬁcant effect on the magnitude of salbutamol-
induced bronchodilation. On VC mode, salbutamol
decreased Rint by 13.179%, 15.4710.5%, 18.479%
and 15.879.9% from baseline at 15, 30, 60 and
120min after its administration, respectively. The
corresponding values on PS mode were 15.776.4%,
16.3711.3%, 18.3711.4% and 13.3710.7%. Simi-
larly, on VC mode salbutamol decreased Rrs by
10.178.8%, 12.779.8%, 13.279.3% and 11.978%
from baseline at 15, 30, 60 and 120min after drug
delivery, respectively, while the corresponding
values on PS mode were 10.375.9%, 12.776.7%,
11.978.9% and 10.876.8%. Figures 2A and B show
individual patient values of Rint before and after
salbutamol administration on VC mode and PS
mode, respectively. Patient no. 2 did not exhibit
any bronchodilator response to salbutamol on PS
mode and only a modest response (Rint decreased
from 14.3 to 12.9 cm H2O/l/s, i.e. 9.8%) on VC
mode. In the remaining 9 patients salbutamol
caused a decrease in Rint that was very similar
both on VC and on PS mode. Regardless of the
ventilatory mode, changes in HR, DR and Crs were
not signiﬁcant at any time interval after salbutamol
administration. SaO2 remained constant throughout
the study, indicating that clinically signiﬁcant
changes in PaO2 as a result of salbutamol adminis-
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Figure 1 Individual values of Rmin before and 60min after
400 mg of salbutamol administration. Open bars: volume
control (VC). Closed bars: pressure support (PS). For a
given patient and mode of drug administration the two
bars represent Rmin at time 0 (before salbutamol
administration, baseline) and at 60min after salbutamol
administration. Rmin at 15 and 30min after salbutamol
administration were omitted for clarity of presentation.
after salbutamol administration in VC mode. Mean
values: closed circles connected by thick solid line.
Baseline value (before salbutamol): time 0. —~— :
patient 1,—— : patient 6,—m— : patient 2,—’— :
patient 7, —n— : patient 3, — K— : patient 8,
— —: patient 4, —p— : patient 9, —J— : patient
5, —B— : patient 10. (B) Individual patient values of
Rmin before and after salbutamol administration in PS
mode. Mean values: closed circles connected by thick
solid line. Baseline value (before salbutamol): time 0.
—E— : patient 1,—— : patient 6,—m— : patient 2,
—’— : patient 7,—n— : patient 3,—K— : patient 8,
— —: patient 4, —&— : patient 9, —J— : patient
5, —B— : patient 10.Discussion
Our work re-conﬁrmed previous studies showing
that in mechanically ventilated COPD patients, b2-
agonists delivered by MDI and a spacer produced a
signiﬁcant and sustained decrease in inspira-
tory resistance indices, namely a maximal Rint
decrease of 18% and an Rrs decrease of approxi-
mately 13%. These values compare rather well with
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ranging between 18% and 25% for Rint and between
8% and 15% for Rrs, respectively,
1–4,18–20 while
baseline respiratory mechanics in these studies
were similar to ours (Rint 14–21 cm H2O/l/s, Rrs
20–26 cm H2O/l/s). Although in the present study
expiratory resistance was not measured, this most
likely was decreased by salbutamol, as indicated by
the signiﬁcant reduction in PEEPi and end-inspira-
tory static plateau pressure, which are indirect
indices of dynamic hyperinﬂation. We further
showed that the response was not inﬂuenced by
the presence of active respiratory efforts during
drug delivery. Indeed, similar bronchodilation was
observed when salbutamol was administered with
volume control and ﬂow-triggered pressure support
and this response was quite consistent within
patients. In accordance with our ﬁndings a study
by Nava et al.21 showed that 400 mg of salbutamol
delivered by MDI and a spacer device resulted in
signiﬁcant bronchodilation during a spontaneous
ventilatory mode, even though their study was
performed during non-invasive mechanical ventila-
tion. With both modes of drug delivery DR
remained relatively constant throughout the study,
indicating that salbutamol acted by dilating the
central airways, in line with previous observa-
tions.1–4,18–20
Target sedation levels of Ramsay score 6 and 3 for
VC and PS, respectively, were chosen in order to
achieve complete absence of respiratory muscle
activity during VC and comparable to VC baseline
breathing pattern parameters during PS with
concomitant near-optimal patient to ventilator
adaptation.
Propofol was used for sedation in our patients
because due to study design a sedative agent with a
short half-life and a rapid elimination rate was
desirable. Propofol seems to have bronchodilatory
properties,22 although this ﬁnding has been chal-
lenged by other in vitro23 and in vivo studies.24 We
believe that propofol administration is unlikely to
have affected our results for the following reasons.
A propofol infusion rate of 3.5mg/kg/h in critically
ill ICU patients results in a plasma concentration of
approximately 2.0 mg/ml25 (during VC our patients
received a slightly higher dose, i.e. 4mg/kg/h),
while according to population-based pharmacoki-
netic models a propofol bolus of 100mg (similar to
that given to our patients during PS before
respiratory system mechanics measurement) re-
sults in a plasma concentration of approximately
2.5 mg/ml at 2min after administration.26 There-
fore, it seems that in our patients resistance was
compared between the two modes of b2-agonist
administration under comparable plasma propofolconcentrations. Furthermore, baseline values of
Rmin and Rrs during the 6 h of observation as well as
the corresponding baseline values between the two
modes (as shown in Table 2) were similar. There-
fore, any difference between modes should be due
to the mode of salbutamol administration and not
to propofol.
A dose of 4 puffs of salbutamol (100 mg/puff) was
used. Previous studies have shown that this dose
ensures the best combination of bronchodilator
effect and safety in mechanically ventilated pa-
tients with COPD.20 Higher doses simply increased
the side effects of the drug (increase in HR),
without any additional bronchodilation.20 This,
however, does not exclude the possibility that in
an individual patient higher doses may be necessary
in order to achieve maximum bronchodilation. For
example, it is not known whether or not patient no.
2 would have responded to a higher dose of
salbutamol.
Previous in vivo1–4 and in vitro27 studies have
shown that during CMV, ventilator settings such as
VT, inspiratory ﬂow rate, inspiratory ﬂow pattern
and duty cycle did not have a signiﬁcant impact on
salbutamol-induced bronchodilation administered
with an MDI adapted to a large volume spacer
device. These studies indicate that the different
ﬂow pattern, ﬂow rate and duty cycle between
volume control and pressure support ventilation
should not be an important determinant of bronch-
odilator response. Similar principle should also
apply to VT, although by study design VTwas similar
between volume control and pressure support.
Based on the in vitro observations by Fink et al.8
of an up to 23% decrease in salbutamol delivery
during CMV compared with simulated spontaneous
breaths of similar VT it has been suggested to apply
transiently higher VTs for aerosol delivery during
controlled ventilation in order to augment bronch-
odilator response.28 However, a former in vivo
study by our group2 showed that the magnitude of
bronchodilation was not affected by a 50% increase
in VT (from 8 to 12ml/kg). It follows that any
difference in bronchodilator response between
volume control and pressure support should be
attributed to the presence of active respiratory
efforts. The similar bronchodilator response be-
tween volume control and pressure support indi-
cates that the presence of active respiratory efforts
during drug administration does not inﬂuence the
magnitude of salbutamol-induced bronchodilation.
One major limitation of our study is the fact that
patient respiratory effort was not quantiﬁed. In
contrast to assist volume control mode, in pressure
support mode the airway pressure waveform cannot
be used to quantify respiratory effort since airway
ARTICLE IN PRESS
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Moreover, a ﬂow-triggering system was used in
pressure support mode and thus the airway pressure
drop before triggering did not reﬂect respiratory
drive since it was mainly dependent on circuit
resistance. Therefore, it is not known if the
magnitude of respiratory effort might be an im-
portant variable inﬂuencing bronchodilator re-
sponse. Nevertheless, during PS our patients were
studied under sedation and a sufﬁcient amount of
PEEP was applied to all of them in order to
counterbalance PEEPi and thus to reduce the initial
threshold load and to increase triggering sensitivity.
Furthermore, in all patients the level of pressure
assist was titrated such that no clinical evidence of
excessive work of breathing was observed, while the
breathing frequency was relatively low (16 breaths/
min). All these interventions may have caused our
patients to relax their muscles after triggering,
reducing considerably the work of breathing. Differ-
ent results might be obtained with increased
respiratory efforts, which are associated with great-
er drug delivery to target sites. Future studies
focusing on respiratory effort quantiﬁcation by
esophageal balloon insertion would be helpful in
resolving this issue. Furthermore, this technique,
although quite cumbersome, has proven useful for
measuring respiratory mechanics in patients with
active respiratory efforts29 and would hence surpass
the need for propofol administration in order to
suppress active respiratory efforts.
In our study salbutamol was given at a dose of
400 mg. This dose was chosen because previous
studies have shown that during CMV 400 mg of
salbutamol caused a near maximum bronchodilator
response with negligible side effects.20 Thus,
although higher doses of salbutamol delivered
during pressure support ventilation may have
different results, studies during CMV do not support
this argument.
In conclusion, our study showed that MDI delivery
of salbutamol during assisted mechanical ventila-
tion in patients with acute exacerbation of COPD
resulted in bronchodilation that was comparable to
that observed when the drug was administered
during CMV. Provided that the technique of admin-
istration is proper, active triggering of the venti-
lator during pressure support ventilation does not
inﬂuence the efﬁciency of bronchodilators in
patients with acute exacerbation of COPD.References
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